SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2025 Earnings: Revenue Beat and Raised Guidance Fuel Pre-Market Rally

SOPHiA GENETICS SA (NASDAQ:SOPH), a global leader in AI-driven precision medicine, has released its financial results for the third quarter of 2025. The company's performance during the period, coupled with an updated outlook for the full year, appears to have generated a notably positive response from investors in pre-market trading.

Third Quarter Financial Results

The company's third-quarter financial results for 2025 surpassed analyst expectations on the top line. SOPHiA GENETICS reported revenue of $19.46 million, which exceeded the consensus estimate of $18.49 million. On the bottom line, the company reported a non-GAAP loss per share of $0.30, which was wider than the estimated loss of $0.25 per share.

• Reported Revenue: $19.46 million
• Estimated Revenue: $18.49 million
• Reported Non-GAAP EPS: -$0.30
• Estimated Non-GAAP EPS: -$0.25

This performance indicates robust demand for the company's services, specifically its SOPHiA DDM platform, even as it continues to invest heavily in growth, resulting in a larger-than-anticipated per-share loss.

Market Reaction and Recent Performance

The market's immediate reaction to the earnings report and guidance update has been strongly positive. The stock is showing significant upward momentum in pre-market trading. This positive sentiment is also reflected in the stock's performance over recent weeks, suggesting building investor optimism leading into the earnings announcement.

• Pre-Market Performance: +7.4%
• Performance Over the Last Month: +23.5%
• Performance Over the Last Two Weeks: +19.3%

The substantial pre-market gain suggests that investors are focusing on the revenue beat and the raised full-year guidance, viewing these as stronger indicators of the company's trajectory than the wider quarterly loss.

Updated 2025 Outlook and Analyst Estimates

A key driver of the positive market sentiment appears to be the company's decision to increase its revenue guidance for the full 2025 fiscal year. While the specific numerical value of the new guidance was not detailed in the provided context, the act of raising its outlook signals to the market that management's confidence in its near-term growth prospects has strengthened. This updated outlook can be contrasted with the existing analyst estimates for the full year.

• Analyst Estimated Full-Year 2025 Revenue: $76.0 million
• Analyst Estimated Full-Year 2025 EPS: -$1.10

For the upcoming fourth quarter, analysts are currently projecting revenue of $20.71 million and a non-GAAP loss per share of $0.24. The company's raised annual guidance implies that its internal forecasts for Q4 and the full year are more optimistic than these current consensus figures.

Press Release Summary

The central announcement from the press release is twofold. First, SOPHiA GENETICS reported its financial results for the third quarter of 2025, demonstrating a solid revenue beat. Second, and perhaps more critically for the stock's movement, the company formally increased its revenue guidance for the full 2025 fiscal year. This combination of strong quarterly sales performance and an upward revision of future expectations forms the core of the positive news.

For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the data available on the SOPH earnings and estimates page.

---

Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The content presented is based on data believed to be reliable but its accuracy cannot be guaranteed. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.